OR2AT4 and OR1A2 counterregulate molecular pathophysiological processes of steroid-resistant inflammatory lung diseases in human alveolar macrophages.
Daniel WeidingerKaschin Jamal JameelDesiree AlischJulian JacobsenPaul BürgerMatthias RuheFaisal YusufSimon RohdeKlemens StörtkuhlPeter KaufmannJuliane KronsbeinMarcus PetersHanns HattNikolaos GiannakisJürgen KnoblochPublished in: Molecular medicine (Cambridge, Mass.) (2022)
These are the first indications for utilizing olfactory receptors as therapeutic target molecules in treating steroid-resistant lung diseases with non-type 2 inflammation.